Özet:

Bone metastasis is usually associated with poor prognosis. Bone scintigraphy (BS) and serum alkaline phosphatase level are used to detect bone metastasis in malignancy. This retrospective study aimed to examine the relationship among bone scintigraphy and serum ALP level in cancer patients. Material-Methods: BS was performed by the i.v. administration of Tc99m-MDP (Methylendiphosphonate) at a dose of about 20mCi. The reference range for ALP level was 35-105 IU/L. Scintigraphic findings of the patients were divided into four groups regarding the number of lesion as; “no metastatic lesion”, “one bone involvement”, “two bones involvement” and “more than three-bones involvement”. Results: Fifty three of 102 patients had breast cancer; 16 patients had lung cancer; 16 patients had prostate cancer; 3 patients had ovary carcinoma, 2 patients had testicle cancer; 2 patients had endometrium cancer; 2 patients had pancreas cancer; 2 patients had gastric cancer; patients had thyroid cancer; 2 patients had rectum cancer; 1 patient had esophagus cancer and 1 patient had bladder cancer. The mean value of serum ALP level was higher in patients with bone metastasis than in patients without bone metastasis. The mean serum level of ALP was;  92.76±26 IU/L in patients with single bone involvement; 106.18±22 IU/L in patients with two bones involvement; 302.92±210 IU/L in patients with more than three-bones involvement and 70.07±17 IU/L in patients without bone metastasis. Conclusion: In our study, while ALP levels were within normal values at patients without metastatic bone lesion and patients monitored with single metastasis, and these were above normal values at patients with 2 lesion; there was a significant increase at patients with 3 or more lesions. Consequently, it’s been thought that controlling the ALP level of patients who had bone scintigraphy for evaluation of the skeletal system metastasis increase the specificity of the bone scintigraphy.

Anahtar Kelimeler: